Oral rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine.

Abstract

ACP Journal Club19 November 2019Oral rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraineLucas McCarthy, MD, MSLucas McCarthy, MD, MSVirginia Mason Medical Center, Seattle, Washington, USA (L.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ201911190-059 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142-9. https://pubmed.ncbi.nlm.nih.gov/31291516Clinical Impact RatingsGIM/FP/GP: Neurology: References1 Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-58. [PMID: 12383060] Google Scholar2 Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114-25. [PMID: 23965396] Google Scholar3 Deen M, Correnti E, Kamm K, et al; European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18:96. [PMID: 28948500] Google Scholar Author, Article, and Disclosure InformationAffiliations: Virginia Mason Medical Center, Seattle, Washington, USA (L.M.)This article was published at Annals.org on 5 November 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOrally disintegrating rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine Lucas McCarthy Metrics 19 November 2019Volume 171, Issue 10Page: JC59KeywordsAdverse eventsCalcitoninMigraineNauseaNumber needed to treatPhase 2 trialsProtease inhibitorsSafetySerious adverse eventsVasodilation ePublished: 19 November 2019 Issue Published: 19 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...